Anton Rx Report

So, when was the last time your company looked at its protocols to safeguard Protected Health Information (PHI)? You know, all that patient-specific information that

So, can you easily explain the differences between a chemically synthesized drug and a biologic?You might be surprised how difficult that has become. The article

We dog eared the article below some time ago but never got around to including it in a weekly Anton Rx Report. It is insightful

Patients on complex specialty therapies always have lots of questions. Lately they have been asking lots of questions about the Covid-19 vaccines and whether they

Curiouser and curiouser…….The pharmacy management rabbit hole seems to be getting curiouser by the day. The article below details a very new and provocative tactic

Specialty pharmacies won’t be dispensing Abecma (idecabtagene vicleucel), approved by the FDA last week. Abecma is an INFUSED cell-based gene therapy to treat adult patients

Last week the FDA approved a new ORAL therapy, Ponvory (ponesimod) from Janssen Pharmaceutical, to treat relapsing forms of Multiple Sclerosis. There is no shortage

Integrated specialty pharmacy services sound so upbeat it is hard to, well, beat. The integration being promoted by health system specialty pharmacies launched in recent

Everyone in the specialty pharmacy business sits up and pays attention whenever a specialty pharmacy is acquired or announces big news. After all, good competition

Last week the FDA approved a new ORAL Oncology therapy, Fotivda (tivozanib) from Aveo Oncology, for the treatment of adult patients with relapsed or refractory